Table 5 Spectral karyotype analysis of... | American Society of Hematology

Table 5

Spectral karyotype analysis of primary and secondary AMLs

Mouse	Phenotype	Tissue	Karyotype (no. cells)*
1586	Primary AML	Spleen	40,XX,t(7;17)(F1;D)[8]/40,XX,der(2)t(X;2)(D;D)[1]/ 40,XX[1]
6753	Secondary AML†	Spleen	40,XX,t(7;17)(F1;D)[7]/41,idem,del(2)(C1H3),+14[2]/ 40,idem,del(12)(BF2)[1]/
4525	Primary AML	Spleen	56,XX,+X,+1,+2,del(3)(BF1),+4,+4,+5,+5,+6,+6,del(6)(B3G3),t(6;12)(D;F1),+10,+11,+14,+15,+16,+17,+19[7]/58,idem,+14,+15[1]/40,XX[3]/40,XY[1]
6755	Secondary AML‡	Spleen	55,XX,+1,del(1)(DE3),+2,del(3)(BF1),+4,+4,+5,+5,+6,+6,del(6)(B3G3),t(6;12)(D;F1),+10,+11,+14,+15,+16,+17,+19[9] /56,idem,+X[3]

Mouse	Phenotype	Tissue	Karyotype (no. cells)*
1586	Primary AML	Spleen	40,XX,t(7;17)(F1;D)[8]/40,XX,der(2)t(X;2)(D;D)[1]/ 40,XX[1]
6753	Secondary AML†	Spleen	40,XX,t(7;17)(F1;D)[7]/41,idem,del(2)(C1H3),+14[2]/ 40,idem,del(12)(BF2)[1]/
4525	Primary AML	Spleen	56,XX,+X,+1,+2,del(3)(BF1),+4,+4,+5,+5,+6,+6,del(6)(B3G3),t(6;12)(D;F1),+10,+11,+14,+15,+16,+17,+19[7]/58,idem,+14,+15[1]/40,XX[3]/40,XY[1]
6755	Secondary AML‡	Spleen	55,XX,+1,del(1)(DE3),+2,del(3)(BF1),+4,+4,+5,+5,+6,+6,del(6)(B3G3),t(6;12)(D;F1),+10,+11,+14,+15,+16,+17,+19[9] /56,idem,+X[3]

A minimum of 10 metaphase cells were analyzed.

Recipient mouse 6753 was transplanted with leukemia cells from primary mouse 1586.

Recipient mouse 6755 was transplanted with leukemia cells from primary mouse 4525.